Back to search results

Proton Stereotactic Body Radiation Therapy for Kidney Cancer

This study is looking at a new way to treat kidney cancer (renal cell carcinoma) using a special type of radiation called Proton Stereotactic Body Radiation Therapy (SBRT). This treatment aims to deliver radiation directly to the tumor while protecting healthy kidney tissue. You might be able to join if you are at least 18 years old, have kidney cancer that hasn't spread, and can't have surgery or other local treatments. The main goal is to see how this treatment affects your kidney function, measured by blood tests (serum creatinine and eGFR) over two years. The study plans to enroll 20 participants.

Study design
This is an interventional study planning to enroll 20 participants. It is not specified if it's randomized or blinded.
What's involved
You would receive 3-5 radiation treatments over 1.5-2 weeks. Your kidney function will be checked with blood tests at the start and every 3-6 months for up to two years after treatment.
Compensation
Not stated in the trial record.
Follow-up
Your kidney function will be monitored for up to two years after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06376669

Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma

Recruiting
PHASE2Ages 18+InterventionalTreatment
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
~20 participants
Updated 2026-04-03 on ClinicalTrials.gov
What's tested:Proton Stereotactic Body Radiation therapy (SBRT)

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in kidney function after PROTON-BASED SBRT treatment as assessed by serum creatine levels
Measured over Baseline and every 3-6 months up to 2 years post treatment
+1 more outcome measured

Conditions

Renal Cell Carcinoma

Explore related trials

Renal Cell Carcinoma

Where it's being run

1 sites across 1 states
District of Columbia1

Study leadership

  • Sherif Shaaban, MD · PRINCIPAL_INVESTIGATOR · Johns Hopkins University

Who to contact

Sherif Shaaban
[email protected]
202-919-2523
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Change in kidney function after PROTON-BASED SBRT treatment as assessed by serum creatine levelsBaseline and every 3-6 months up to 2 years post treatment

    Change in serum creatine levels from Baseline visit.

  • Change in kidney function after PROTON-BASED SBRT treatment as assessed by estimated glomerular rate (eGFR) valuesBaseline and every 3-6 months up to 2 years post treatment

    Change in eGFR values from Baseline visit.